eMedicine Specialties > Dermatology > Allergy & Immunology

Urticaria, Solar

Author: Ani L Tajirian, MD, Resident Physician, Department of Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Coauthor(s): Philip J Cohen, MD, Chief, Section of Dermatology, New Jersey Veterans Affairs Medical Center
Contributor Information and Disclosures

Updated: Nov 25, 2009

Introduction

Background

Solar urticaria is a rare photodermatosis characterized by pruritus, stinging, erythema, and wheal formation after a brief period of exposure to natural sunlight or an artificial light source emitting the appropriate wavelength.

Initially described by Merklen in 1904, solar urticaria is localized to exposed areas of the skin, although it can occur through thin clothing. Solar urticaria disappears within several minutes to a few hours, without pigmentary change if further sun exposure is avoided. Solar urticaria can be quite disabling and difficult to manage. Solar urticaria often has a sudden, dramatic onset, and little information is available regarding its duration and eventual outcome.

Pathophysiology

Solar urticaria is possibly caused by an antigen-antibody reaction. Solar irradiation may induce an antigen in the serum or plasma of affected individuals. Intradermal injection of serum from a solar urticaria patient passively, but not consistently, transfers the condition to a healthy individual.

The following types of solar urticaria have been proposed:

  • Type I: This type is an immunoglobulin E (IgE)–mediated hypersensitivity to specific photoallergens generated only in solar urticaria patients.
  • Type II: This type is an IgE-mediated hypersensitivity to nonspecific photoallergens found in both solar urticaria patients and healthy individuals.

Passive transfer test findings are positive in patients with type II solar urticaria, but they may be positive or negative in those with type I.

The wide action spectrum (290-800 nm) implicated for this condition may be related to the specific photoallergen and its molecular weight. Diversity in the reported action spectra may be due to differences in photoallergens. In addition, spectra believed to be responsible for either inhibition or augmentation of the reaction have been detected. Complex interactions occur between the various wavelengths and the photoallergen.1

The result of these interactions is mast cell degranulation with subsequent histamine release. Mediators other than histamines may also be involved. Inhibition of solar urticaria with light suppresses the wheal-flare response following intradermal injection of photoactivated autologous serum but does not suppress the wheal and flare associated with compound 48/80.2  

Frequency

United States

Solar urticaria comprises only 4% of US patients with photosensitive disorders.

International

Solar urticaria comprises 5.3% of the cases of photosensitive dermatoses worldwide.

Mortality/Morbidity

The mortality rate for solar urticaria has not been determined. In some cases, skin eruption is accompanied by symptoms such as headache, nausea, vomiting, bronchospasm, and syncope.

Race

Solar urticaria occurs in all races.

Sex

A slight female predilection is noted for solar urticaria.

Age

Solar urticaria has a wide range of onset (10-70 y). The mean age of onset for solar urticaria is 35 years, but it has been reported to occur in infancy.3

Clinical

History

An accurate history is important for the diagnosis of solar urticaria because of the transient nature of the eruption. Patients often have no obvious lesions.

  • Patients may report pruritus, erythema, and wheal formation of varying degrees after a short period (<30 min) of sun exposure.
    • As with most other photodermatoses, skin lesions in solar urticaria may occur on any exposed area, even if skin was covered with thin clothing.
    • The face and the dorsal aspect of the hands, which are chronically exposed to the sun, are less severely affected than other parts of the body, perhaps owing to acclimatization and "hardening."
  • Mucosal involvement (eg, tongue and/or lip swelling) has been reported.
  • Other symptoms, such as headache, nausea, vomiting, bronchospasm, and syncope, have been reported but are considered rare.
  • Upon cessation of sun exposure, the rash begins to disappear within several minutes to a few hours and rarely lasts beyond 24 hours. Rapid disappearance of the rash upon cessation of further sun exposure is essential to the diagnosis of solar urticaria.
  • Ascertain the following aspects of history to exclude other differential diagnoses:
    • Oral medication intake (eg, chlorpromazine), which may cause a similar photo-induced reaction
    • Currently used topical agents (eg, sunscreen, fragrance), which can cause photocontact dermatitis
    • Family history of photosensitivity (as may occur in some porphyrias)
    • Medical history regarding other body systems in order to detect other underlying causes of photosensitivity (eg, connective-tissue disorders)

Physical

In most cases of solar urticaria, physical examination findings will be normal.

  • During an acute episode of solar urticaria, vital signs are usually unaffected; however, systemic symptoms accompanying the cutaneous eruption have been reported.
    • In rare cases, cardiac and respiratory rates increase and blood pressure decreases.
    • Wheezing may be heard upon auscultation of the chest when bronchospasm is present.
  • Examination of the skin during an acute solar urticaria episode may reveal lesions in the form of erythematous macules to distinct wheals, the morphology of which may be no different from that of lesions found in acute urticaria secondary to other causes.
    • Eruption follows a photodistribution modified by the type of clothing worn by the affected individual at the time of exposure.
    • Lesions may be present in areas covered with thin clothing, depending on the causative light wavelength and sheerness of the fabric.
    • Mucosal areas, such as the tongue and lips, may be swollen or edematous.
    • The reaction leaves no residual skin changes. Consequently, examination of the skin after the acute eruption reveals no evidence of the condition.

Causes

Solar urticaria may be caused by an antigen-antibody reaction. Solar irradiation may induce an antigen in the serum or plasma of affected individuals. Intradermal injection of serum from a solar urticaria patient passively, but not consistently, transfers the condition to a healthy individual.

More on Urticaria, Solar

Overview: Urticaria, Solar
Differential Diagnoses & Workup: Urticaria, Solar
Treatment & Medication: Urticaria, Solar
Follow-up: Urticaria, Solar
References

References

  1. Miyauchi H, Horio T. Detection of action, inhibition and augmentation spectra in solar urticaria. Dermatology. 1995;191(4):286-91. [Medline].

  2. Fukunaga A, Horikawa T, Yamamoto A, Yamada Y, Nishigori C. The inhibition spectrum of solar urticaria suppresses the wheal-flare response following intradermal injection with photo-activated autologous serum but not with compound 48/80. Photodermatol Photoimmunol Photomed. Jun 2006;22(3):129-32. [Medline].

  3. Harris A, Burge SM, George SA. Solar urticaria in an infant. Br J Dermatol. Jan 1997;136(1):105-7. [Medline].

  4. Lecha M, Puy H, Deybach JC. Erythropoietic protoporphyria. Orphanet J Rare Dis. Sep 10 2009;4:19. [Medline].

  5. Hughes R, Cusack C, Murphy GM, Kirby B. Solar urticaria successfully treated with intravenous immunoglobulin. Clin Exp Dermatol. Jun 17 2009;[Medline].

  6. Maksimovic L, Fremont G, Jeanmougin M, Dubertret L, Viguier M. Solar urticaria successfully treated with intravenous immunoglobulins. Dermatology. 2009;218(3):252-4. [Medline].

  7. Dawe RS, Ferguson J. Prolonged benefit following ultraviolet A phototherapy for solar urticaria. Br J Dermatol. Jul 1997;137(1):144-8. [Medline].

  8. Collins P, Ahamat R, Green C, Ferguson J. Plasma exchange therapy for solar urticaria. Br J Dermatol. Jun 1996;134(6):1093-7. [Medline].

  9. Fotiades J, Soter NA, Lim HW. Results of evaluation of 203 patients for photosensitivity in a 7.3-year period. J Am Acad Dermatol. Oct 1995;33(4):597-602. [Medline].

  10. Khoo SW, Tay YK, Tham SN. Photodermatoses in a Singapore skin referral centre. Clin Exp Dermatol. Jul 1996;21(4):263-8. [Medline].

  11. Roelandts R. Diagnosis and treatment of solar urticaria. Dermatol Ther. 2003;16(1):52-6. [Medline].

  12. Roelandts R, Ryckaert S. Solar urticaria: the annoying photodermatosis. Int J Dermatol. Jun 1999;38(6):411-8. [Medline].

  13. Ryckaert S, Roelandts R. Solar urticaria. A report of 25 cases and difficulties in phototesting. Arch Dermatol. Jan 1998;134(1):71-4. [Medline].

  14. Shimauchi T, Kabashima K, Tokura Y. Solar urticaria as a manifestation of Churg-Strauss syndrome. Clin Exp Dermatol. Mar 2007;32(2):209-10. [Medline].

Further Reading

Keywords

solar urticaria, sun hives, allergy, allergic reaction, anaphylaxis, anaphylactoid reaction, angioedema, photodermatosis, pruritus, solar irradiation, minimum urticarial dose, MUD, polymorphous light eruption, PMLE, erythropoietic protoporphyria, lupus erythematosus, photocontact dermatitis, miliaria rubra, psoralen–UV-A, PUVA, phototherapy, UV-A, broadband UV-B, narrowband UV-B, photochemotherapy, methoxsalen

Contributor Information and Disclosures

Author

Ani L Tajirian, MD, Resident Physician, Department of Dermatology, University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Disclosure: Nothing to disclose.

Coauthor(s)

Philip J Cohen, MD, Chief, Section of Dermatology, New Jersey Veterans Affairs Medical Center
Disclosure: Nothing to disclose.

Medical Editor

Donald Belsito, MD, Clinical Professor, Department of Internal Medicine, Division of Dermatology, University of Missouri at Kansas City; Private Practice, American Dermatology Associates, LLC
Donald Belsito, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, Dermatology Foundation, Kansas Medical Society, Noah Worcester Dermatological Society, Phi Beta Kappa, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Pharmacy Editor

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center
Michael J Wells, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

Managing Editor

Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio
Jeffrey Meffert, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, Association of Military Dermatologists, and Texas Dermatological Society
Disclosure: Nothing to disclose.

CME Editor

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania
Joel M Gelfand, MD, MSCE is a member of the following medical societies: Society for Investigative Dermatology
Disclosure: AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis  investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.